Veracyte shares surge 12.13% after-hours as Q3 earnings and revenue exceed estimates, with raised 2025 guidance.

Veracyte Inc. (NASDAQ: VCYT) surged 12.13% in after-hours trading following the release of strong Q3 2025 financial results, which included a 59.38% earnings surprise (EPS of $0.51 vs. $0.32 expected) and revenue of $131.9M, exceeding forecasts of $124.85M. The company raised its full-year 2025 revenue guidance to $506M–$510M, reflecting confidence in diagnostic product growth, including Afirma and Decipher tests. Analyst upgrades further fueled optimism, with Needham raising its price target to $44 and Freedom Capital initiating coverage at $45, citing leadership in cancer diagnostics and innovative tools like Afirma GRID. The stock’s rally aligned with improved gross margins, a debt-free balance sheet, and strategic initiatives such as MRD testing and European kitted test expansions, reinforcing expectations of sustained double-digit revenue growth.